Cargando…

Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment

BACKGROUND: The objectives of this review were to evaluate the vaccine effectiveness (VE) of the two-dose varicella vaccine for healthy children in China and explore the application of the approach of Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) in observational studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhujiazi, Suo, Luodan, Pan, Jingbin, Zhao, Dan, Lu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188742/
https://www.ncbi.nlm.nih.gov/pubmed/34107891
http://dx.doi.org/10.1186/s12879-021-06217-1
_version_ 1783705386232053760
author Zhang, Zhujiazi
Suo, Luodan
Pan, Jingbin
Zhao, Dan
Lu, Li
author_facet Zhang, Zhujiazi
Suo, Luodan
Pan, Jingbin
Zhao, Dan
Lu, Li
author_sort Zhang, Zhujiazi
collection PubMed
description BACKGROUND: The objectives of this review were to evaluate the vaccine effectiveness (VE) of the two-dose varicella vaccine for healthy children in China and explore the application of the approach of Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) in observational studies on VE. METHODS: We searched for observational studies on two-dose varicella VE for children in China aged 1–12 years that were published from 1997 to 2019, and assessed the quality of each study using the Newcastle Ottawa Scale (NOS). We used meta-analysis models to obtain the pooled two-dose VE, and the studies were divided into subgroups and analysed according to whether or not it was an outbreak investigation and its NOS score. The quality of evidence of VEs were rated by approach of the GRADE system. RESULTS: A total of 12 studies and 87,196 individuals were included. The pooled two-dose VE was 90% (95% confidence interval [CI]: 69–97%). The VE of outbreak studies (87% [95% CI: 76–93%]) was lower than non-outbreak studies (99% [95% CI: 98–99%]). There was no significant difference in VEs by different NOS quality. The quality of the evidence assessment of pooled two-dose VE was “low”, which was rated down by one category in limitations and publication bias respectively and rated up by two category in large effect. The quality of evidence assessment in subgroup of NOS score ≥ 7 was “moderate”. CONCLUSIONS: The VE of two-dose varicella vaccine is relatively high in preventing varicella, and is recommended for countries which need further control for varicella. However, higher quality evidence is needed as a supplement for stronger recommendations. The approach of GRADE could be applied for rating the quality of evidence in observational study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06217-1.
format Online
Article
Text
id pubmed-8188742
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81887422021-06-10 Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment Zhang, Zhujiazi Suo, Luodan Pan, Jingbin Zhao, Dan Lu, Li BMC Infect Dis Research Article BACKGROUND: The objectives of this review were to evaluate the vaccine effectiveness (VE) of the two-dose varicella vaccine for healthy children in China and explore the application of the approach of Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) in observational studies on VE. METHODS: We searched for observational studies on two-dose varicella VE for children in China aged 1–12 years that were published from 1997 to 2019, and assessed the quality of each study using the Newcastle Ottawa Scale (NOS). We used meta-analysis models to obtain the pooled two-dose VE, and the studies were divided into subgroups and analysed according to whether or not it was an outbreak investigation and its NOS score. The quality of evidence of VEs were rated by approach of the GRADE system. RESULTS: A total of 12 studies and 87,196 individuals were included. The pooled two-dose VE was 90% (95% confidence interval [CI]: 69–97%). The VE of outbreak studies (87% [95% CI: 76–93%]) was lower than non-outbreak studies (99% [95% CI: 98–99%]). There was no significant difference in VEs by different NOS quality. The quality of the evidence assessment of pooled two-dose VE was “low”, which was rated down by one category in limitations and publication bias respectively and rated up by two category in large effect. The quality of evidence assessment in subgroup of NOS score ≥ 7 was “moderate”. CONCLUSIONS: The VE of two-dose varicella vaccine is relatively high in preventing varicella, and is recommended for countries which need further control for varicella. However, higher quality evidence is needed as a supplement for stronger recommendations. The approach of GRADE could be applied for rating the quality of evidence in observational study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06217-1. BioMed Central 2021-06-09 /pmc/articles/PMC8188742/ /pubmed/34107891 http://dx.doi.org/10.1186/s12879-021-06217-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Zhujiazi
Suo, Luodan
Pan, Jingbin
Zhao, Dan
Lu, Li
Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title_full Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title_fullStr Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title_full_unstemmed Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title_short Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment
title_sort two-dose varicella vaccine effectiveness in china: a meta-analysis and evidence quality assessment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188742/
https://www.ncbi.nlm.nih.gov/pubmed/34107891
http://dx.doi.org/10.1186/s12879-021-06217-1
work_keys_str_mv AT zhangzhujiazi twodosevaricellavaccineeffectivenessinchinaametaanalysisandevidencequalityassessment
AT suoluodan twodosevaricellavaccineeffectivenessinchinaametaanalysisandevidencequalityassessment
AT panjingbin twodosevaricellavaccineeffectivenessinchinaametaanalysisandevidencequalityassessment
AT zhaodan twodosevaricellavaccineeffectivenessinchinaametaanalysisandevidencequalityassessment
AT luli twodosevaricellavaccineeffectivenessinchinaametaanalysisandevidencequalityassessment